RxDoctor Payments DataLook up a doctor →

Daniel Englert, MD

Family Medicine · Huntsville, ALNPI 1760916282

Payments from drug & device makers

$81,581in general payments, 2019–2025

Across 1,049 payments — averaging $77.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$31K
  • AbbVie$21K
  • Phathom Pharmaceuticals, Inc.$15K
  • Novo Nordisk$3K
  • AstraZeneca$1K
  • GSK$747
  • plus $9K from 44 others

What the payments were for

  • Speaking & faculty fees$51,53063%
  • Travel & lodging$10,46613%
  • Food & beverage$19,41024%
  • Education$1760%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$81,581 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$142,389
Medicare patients
302
Services billed
1,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$195,129
RexultiBrexpiprazole72$123,756
JardianceEmpagliflozin78$106,244
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$70,130
EliquisApixaban71$70,029
VraylarCariprazine Hcl38$65,182
RybelsusSemaglutide20$50,821
MounjaroTirzepatide36$48,967
FarxigaDapagliflozin Propanediol49$42,242
TrulicityDulaglutide23$36,283
MyrbetriqMirabegron47$29,620
JanuviaSitagliptin Phosphate19$21,889
ProliaDenosumab12$20,497
EntrestoSacubitril/Valsartan11$14,187
Synjardy XrEmpagliflozin/Metformin Hcl11$8,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,783$245,950147 claims
Otsuka America Pharmaceutical, Inc.Rexulti$31,074$123,75672 claims
Boehringer IngelheimJardiance, Synjardy Xr$217$114,99489 claims
Lilly USA, LLCMounjaro, Trulicity$707$85,25059 claims
GSKTrelegy Ellipta$747$70,13067 claims
PfizerEliquis$472$70,02971 claims
AbbVieVraylar, Synthroid$21,273$68,08170 claims
AstraZenecaFarxiga$1,231$42,24249 claims
Astellas Pharma US IncMyrbetriq$703$29,62047 claims
MerckJanuvia$61$21,88919 claims
AmgenProlia$623$20,49712 claims
NovartisEntresto$96$14,18711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →